Pierre Bedossa
Overview
Explore the profile of Pierre Bedossa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
297
Citations
15243
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zambon Azevedo V, Bel Lassen P, Aron-Wisnewsky J, Genser L, Charlotte F, Bedossa P, et al.
Clin Nutr
. 2024 Nov;
43(12):254-264.
PMID: 39536396
Background & Aims: Sarcopenic obesity (SO) is associated with cardiometabolic disorders and steatotic liver disease and carries major health risks. We assessed the hepatic and metabolic clinical phenotype associated with...
2.
Le Corvec M, Farrugia M, Nguyen-Khac E, Regimbeau J, Dharhri A, Chatelain D, et al.
Sci Rep
. 2024 Nov;
14(1):26452.
PMID: 39488538
Metabolic dysfunction-associated steatotic liver disease (MASLD) is common in individuals with obesity. Sexual dimorphism is present in MASLD. A noninvasive test to diagnose the severity of the disease, in particular...
3.
Loomba R, Bedossa P, Grimmer K, Kemble G, Martins E, McCulloch W, et al.
Lancet Gastroenterol Hepatol
. 2024 Oct;
9(12):1090-1100.
PMID: 39396529
Background: Denifanstat, an oral fatty acid synthase (FASN) inhibitor, blocks de-novo lipogenesis, a key pathway driving progressive lipotoxicity, inflammation, and fibrosis in metabolic dysfunction-associated steatohepatitis (MASH). This study aimed to...
4.
Sharma A, Godina Leiva E, Kalavalapalli S, Lomonaco R, Marangi S, Valdez Saenz E, et al.
Obesity (Silver Spring)
. 2024 Sep;
32(10):1967-1974.
PMID: 39315409
Objective: The objective of this study was to determine the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in young compared with older adults. Methods: Individuals (n = 1420) with...
5.
Pulaski H, Mehta S, Manigat L, Kaufman S, Hou H, Nalbantoglu I, et al.
J Pathol Clin Res
. 2024 Sep;
10(5):e12395.
PMID: 39294925
The gold standard for enrollment and endpoint assessment in metabolic dysfunction-associated steatosis clinical trials is histologic assessment of a liver biopsy performed on glass slides. However, obtaining the evaluations from...
6.
Liu F, Sun Y, Tai D, Ren Y, Chng E, Wee A, et al.
Diagnostics (Basel)
. 2024 Aug;
14(16).
PMID: 39202325
This study aimed to understand the dynamic changes in fibrosis and its relationship with the evaluation of post-treatment viral hepatitis using qFibrosis. A total of 158 paired pre- and post-treatment...
7.
Hvid H, Hjuler S, Bedossa P, Tiniakos D, Kamzolas I, Harder L, et al.
Am J Physiol Gastrointest Liver Physiol
. 2024 Jul;
327(4):G571-G585.
PMID: 39041677
The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) is increasing, and translational animal models are needed to develop novel treatments for this disease. The...
8.
Vacca M, Kamzolas I, Harder L, Oakley F, Trautwein C, Hatting M, et al.
Nat Metab
. 2024 Jun;
6(6):1178-1196.
PMID: 38867022
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease, encompasses steatosis and metabolic dysfunction-associated steatohepatitis (MASH), leading to cirrhosis and hepatocellular carcinoma. Preclinical MASLD research is...
9.
Sanyal A, Bedossa P, Fraessdorf M, Neff G, Lawitz E, Bugianesi E, et al.
N Engl J Med
. 2024 Jun;
391(4):311-319.
PMID: 38847460
Background: Dual agonism of glucagon receptor and glucagon-like peptide-1 (GLP-1) receptor may be more effective than GLP-1 receptor agonism alone for treating metabolic dysfunction-associated steatohepatitis (MASH). The efficacy and safety...
10.
Clouston A, Gouw A, Tiniakos D, Bedossa P, Brunt E, Callea F, et al.
Histopathology
. 2024 May;
85(4):549-561.
PMID: 38773813
Liver biopsies have consistently contributed to our understanding of the pathogenesis and aetiologies of acute liver disease. As other diagnostic modalities have been developed and refined, the role of biopsy...